Endoprotech
Louisville, US · 1 known investors
EndoProTech develops anti-inflammatory liposomes designed to modify the composition of cell plasma membranes and reduce microvascular dysfunction following ischemia/reperfusion injury. Its research targets reducing infarct size after myocardial infarction while preserving tissue viability and shortening recovery time.
Founders & leadership
CM
Claudio MaldonadoFounder, President and CEO
GP
Gustavo Perez-AbadiaFounder, Vice President, and Treasurer
FG
Federico GrossiFounder
PB
Philip BauerBoard Secretary and Senior Scientist
Investors · 1
Frequently asked questions
- What does Endoprotech do?
- EndoProTech develops anti-inflammatory liposomes designed to modify the composition of cell plasma membranes and reduce microvascular dysfunction following ischemia/reperfusion injury. Its research targets reducing infarct size after myocardial infarction while preserving tissue viability and shortening recovery time.
- Who founded Endoprotech?
- Endoprotech was founded by Claudio Maldonado, Gustavo Perez-Abadia, Federico Grossi.
- Who are Endoprotech's investors?
- Endoprotech's investors include Keyhorse Capital.
- Where is Endoprotech headquartered?
- Endoprotech is headquartered in Louisville, US.